Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits.

To delineate the metabolic fate of thyroid hormone in prolonged critically ill rabbits, we investigated the impact of two dose regimes of thyroid hormone on plasma 3,3'-diiodothyronine (T(2)) and T(4)S, deiodinase type 1 (D1) and D3 activity, and tissue iodothyronine levels in liver and kidney, as compared with saline and TRH. D2-expressing tissues were ignored. The regimens comprised either substitution dose or a 3- to 5- fold higher dose of T(4) and T(3), either alone or combined, targeted to achieve plasma thyroid hormone levels obtained by TRH. Compared with healthy animals, saline-treated ill rabbits revealed lower plasma T(3) (P=0.006), hepatic T(3) (P=0.02), and hepatic D1 activity (P=0.01). Substitution-dosed thyroid hormone therapy did not affect these changes except a further decline in plasma (P=0.0006) and tissue T(4) (P=0.04). High-dosed thyroid hormone therapy elevated plasma and tissue iodothyronine levels and hepatic D1 activity, as did TRH. Changes in iodothyronine tissue levels mimicked changes in plasma. Tissue T(3) and tissue T(3)/reverse T(3) ratio correlated with deiodinase activities. Neither substitution- nor high-dose treatment altered plasma T(2). Plasma T(4)S was increased only by T(4) in high dose. We conclude that in prolonged critically ill rabbits, low plasma T(3) levels were associated with low liver and kidney T(3) levels. Restoration of plasma and liver and kidney tissue iodothyronine levels was not achieved by thyroid hormone in substitution dose but instead required severalfold this dose. This indicates thyroid hormone hypermetabolism, which in this model of critical illness is not entirely explained by deiodination or by sulfoconjugation.

[1]  G. Van den Berghe,et al.  Regulation of type 1 deiodinase activity in prolonged critical illness , 2006, Critical Care.

[2]  S. Fiering,et al.  Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. , 2006, Endocrinology.

[3]  G. Van den Berghe,et al.  Tissue thyroid hormone levels in critical illness. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  G. Van den Berghe,et al.  Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. , 2005, Endocrinology.

[5]  G. Van den Berghe,et al.  Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  J. Harney,et al.  Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. , 2005, The Journal of clinical investigation.

[7]  M. Hays,et al.  Alternate pathways of thyroid hormone metabolism. , 2005, Thyroid : official journal of the American Thyroid Association.

[8]  G. Van den Berghe,et al.  Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  G. Van den Berghe,et al.  Endocrine interventions in the ICU. , 2005, European journal of internal medicine.

[10]  J. Harney,et al.  Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. , 2005, Endocrinology.

[11]  W. Wiersinga.  Nonthyroidal illness [ch. 11D] , 2005 .

[12]  G. Van den Berghe,et al.  Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. , 2004, Endocrinology.

[13]  G. Van den Berghe,et al.  Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. , 2003, Endocrinology.

[14]  G. Van den Berghe,et al.  Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  V. Darras,et al.  Changes in thyroid hormone levels in chicken liver during fasting and refeeding. , 2002, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[16]  G. Van den Berghe,et al.  The combined administration of GH‐releasing peptide‐2 (GHRP‐2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP‐2 alone , 2002, Clinical endocrinology.

[17]  G. Van den Berghe,et al.  A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. , 2002, Endocrinology.

[18]  P. Larsen,et al.  Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. , 2002, Endocrine reviews.

[19]  G. Van den Berghe.  Dynamic neuroendocrine responses to critical illness. , 2002, Frontiers in neuroendocrinology.

[20]  Distinct Tissue-Specific Roles for Thyroid Hormone Receptors β and α1 in Regulation of Type 1 Deiodinase Expression , 2001 .

[21]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[22]  L. J. Groot,et al.  Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome , 1999 .

[23]  G. Van den Berghe,et al.  Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. , 1998, The Journal of clinical endocrinology and metabolism.

[24]  E. Fliers,et al.  Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  G. Van den Berghe,et al.  Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone‐secretagogues , 1997, Clinical endocrinology.

[26]  B. Shih,et al.  Increased urinary thyroxine sulfate excretion in thyroxine therapy. , 1997, Endocrine journal.

[27]  V. Darras,et al.  Plasma thyroid hormone levels and iodothyronine deiodinase activity following an acute glucocorticoid challenge in embryonic compared with posthatch chickens. , 1996, General and comparative endocrinology.

[28]  B. Bernard,et al.  Impaired thyroxine and 3,5,3'-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  G. Evans.  Removal of blood from laboratory mammals and birds , 1994, Laboratory animals.

[30]  B. A. O'Mara,et al.  Pretranslational regulation of type I 5'-deiodinase by thyroid hormones and in fasted and diabetic rats. , 1993, Endocrinology.

[31]  M. Kaplan,et al.  Reduced tissue thyroid hormone levels in fatal illness. , 1993, Metabolism: clinical and experimental.

[32]  Removal of blood from laboratory mammals and birds. First report of the BVA/FRAME/RSPCA/UFAW Joint Working Group on Refinement. , 1993, Laboratory animals.

[33]  V. Darras,et al.  Ontogeny of type I and type III deiodinase activities in embryonic and posthatch chicks: relationship with changes in plasma triiodothyronine and growth hormone levels. , 1992, Comparative biochemistry and physiology. Comparative physiology.

[34]  F. Santini,et al.  A radioimmunoassay for measurement of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. , 1992, The Journal of clinical endocrinology and metabolism.

[35]  P. Curran,et al.  The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. , 1991, Endocrine reviews.

[36]  T. Visser,et al.  Effects of propylthiouracil on the biliary clearance of thyroxine (T4) in rats: decreased excretion of 3,5,3'-triiodothyronine glucuronide and increased excretion of 3,3',5'-triiodothyronine glucuronide and T4 sulfate. , 1989, Endocrinology.

[37]  D. J. Millward,et al.  The influence of plasma concentrations of tri-iodothyronine on the acute increases in insulin and muscle protein synthesis in the refed fasted rat. , 1988, The Journal of endocrinology.

[38]  T. Visser,et al.  Deiodination of thyroid hormone by human liver. , 1988, The Journal of clinical endocrinology and metabolism.

[39]  T. Visser,et al.  Development of a radioimmunoassay for triiodothyronine sulfate. , 1988, Journal of immunoassay.

[40]  S. Massry,et al.  Thyroxine transfer and distribution in critical nonthyroidal illnesses, chronic renal failure, and chronic ethanol abuse. , 1987, The Journal of clinical endocrinology and metabolism.

[41]  T. Jolín.  Diabetes decreases liver and kidney nuclear 3,5,3'-triiodothyronine receptors in rats. , 1987, Endocrinology.

[42]  G. Brent,et al.  Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. , 1986, The Journal of clinical endocrinology and metabolism.

[43]  M. Obregon,et al.  Effects of maternal hypothyroidism on the weight and thyroid hormone content of rat embryonic tissues, before and after onset of fetal thyroid function. , 1985, Endocrinology.

[44]  T. Visser,et al.  Rapid and selective inner ring deiodination of thyroxine sulfate by rat liver deiodinase. , 1985, Endocrinology.

[45]  C. J. Pearce,et al.  Iodothyronine kinetics in the rabbit: an experimental model. , 1985, The Journal of endocrinology.

[46]  F. Roelfsema,et al.  Sources and quantity of 3,5,3'-triiodothyronine in several tissues of the rat. , 1983, The Journal of clinical investigation.

[47]  A. Mason,et al.  Hypermetabolic low triiodothyronine syndrome of burn injury , 1982, Critical care medicine.

[48]  W. Wiersinga,et al.  Alterations in hepatic nuclear binding of triiodothyronine in experimental diabetes mellitus in rats. , 1982, Acta endocrinologica.

[49]  E. Kaptein,et al.  Thyroxine metabolism in the low thyroxine state of critical nonthyroidal illnesses. , 1981, The Journal of clinical endocrinology and metabolism.

[50]  J. Robbins,et al.  Thyroid hormone metabolism in primary cultured rat hepatocytes. Effects of glucose, glucagon, and insulin. , 1981, The Journal of clinical investigation.

[51]  P. Larsen,et al.  Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. , 1981, Endocrine reviews.

[52]  T. Visser,et al.  Radioimmunoassay of 3,3'-di-iodothyronine in unextracted serum: the effect of endogenous tri-iodothyronine. , 1978, The Journal of endocrinology.

[53]  J. Chambers,et al.  The production and metabolism of 3,5,3'-triiodothyronine and 3,3',5-triiodothyronine in normal and fasting subjects. , 1978, The Journal of clinical endocrinology and metabolism.

[54]  S. Nagataki,et al.  Serum concentrations, metabolic clearance rates, and production rates of reverse triiodothyronine, triiodothyronine, and thyroxine in starved rabbits. , 1978, Endocrinology.

[55]  B. N. Premachandra,et al.  Radioimmunoassay of reverse triiodothyronine. , 1978, The Journal of clinical endocrinology and metabolism.

[56]  P. Larsen,et al.  The contribution of local tissue thyroxine monodeiodination to the nuclear 3,5,3'-triiodothyronine in pituitary, liver, and kidney of euthyroid rats. , 1978, Endocrinology.

[57]  P. Larsen,et al.  Contributions of plasma triiodothyronine and local thyroxine monodeiodination to triiodothyronine to nuclear triiodothyronine receptor saturation in pituitary, liver, and kidney of hypothyroid rats. Further evidence relating saturation of pituitary nuclear triiodothyronine receptors and the acute in , 1978, The Journal of clinical investigation.

[58]  T. Visser,et al.  Radioimmunoassay of reverse tri-iodothyronine. , 1977, The Journal of endocrinology.

[59]  D. Solomon,et al.  Reciprocal Changes in Serum Concentrations of 3,3′,5′-Triiodothyronine (Reverse T3) and 3,3′5-Triiodothyronine (T3) in Systemic Illnesses , 1975 .

[60]  D. Solomon,et al.  Reciprocal changes in serum concentrations of 3,3',5-triiodothyronine (T3) in systemic illnesses. , 1975, The Journal of clinical endocrinology and metabolism.

[61]  C. Irvine.  Concentration of thyroxine in cellular and extracellular tissues of the sheep and the rate of equilibration of labeled thyroxine. , 1974, Endocrinology.

[62]  S. Reichlin,et al.  Tissue thyroid hormone concentration of rat and man determined by radiommunoassay: biologic significance. , 1973, The Mount Sinai journal of medicine, New York.

[63]  P. Snyder,et al.  Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones. , 1972, Journal of Clinical Investigation.

[64]  G. Steiner,et al.  Influence of heparin on serum free thyroxine. , 1969, The Journal of clinical endocrinology and metabolism.